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Background: c-MET is an oncogene protein that plays important role in gastric carcinogenesis and has been
introduced as a prognostic marker and potential therapeutic target. The aim of this study was to evaluate the
frequency of c-MET overexpression and its relationship with clinicopathological variables in gastric cancer of Iranian
population using tissue microarray.
Methods: In a cross sectional study, representative paraffin blocks of 130 patients with gastric carcinoma treated by
curative gastrectomy during a 2 years period of 2008–2009 in two university hospitals in Tehran-Iran were collected
in tissue microarray and c-MET expression was studied by immunohistochemical staining.
Results: Finally 124 cases were evaluated, constituted of 99 male and 25 female with the average age of 61.5 years.
In 71% (88/124) of tumors, c-MET high expression was found. c-MET high expression was more associated with
intestinal than diffuse tumor type (P = 0.04), deeper tumor invasion, pT3 and pT4 versus pT1 and pT2 (P = 0.014),
neural invasion (P = 0.002) and advanced TNM staging, stage 3 and 4 versus stage 1 and2 (P = 0.044). The c-MET
high expression was not associated with age, sex, tumor location, differentiation grade and distant metastasis, but
relative associations with lymph node metastasis (P = 0.065) and vascular invasion (P = 0.078) were observed.
Conclusions: c-MET oncogene protein was frequently overexpressed in Iranian gastric carcinomas and it was
related to clinicopathological characteristics such as tumor type, depth of invasion, neural invasion and TNM
staging. It can also support the idea that c-MET is a potential marker for target therapy in Iranian gastric cancer.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/9744598757151429
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Gastric carcinoma is currently the second leading cause
of cancer death in the world. Globally its incidence and
mortality declined through the past decades; however it
remains the fourth most common cancer in the world. It
is estimated that close to one million new cases are
occur each year in the world and more than 700.000
deaths are directly related to this problem[1,2].* Correspondence: hashemiforough@yahoo.com
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reproduction in any medium, provided the orIn Iran, gastric cancer is the second most common and
accounts for 10% of all cancers and is the first cause of
cancer related mortality in both sexes [3,4]. More than
7300 new cases are occurred annually which mostly pre-
sented in stage III and IV and half of them died before the
first year of diagnosis. The overall 5-year survival rate of
gastric cancer in Iran was 12.8% which is dramatically
lower than Japan and developed western countries [4,5].
Surgical approach with or without chemotherapy and/
or radiotherapy are the most common modes of therapy.
Succumbing to gastric cancer is usually due to local re-
currence and distant metastasis, and long term survival
after distant metastasis is very low [6].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mation about the mechanisms of gastric carcinogenesis
are remarkably improved [7-9]. It is widely accepted that
gastric carcinogenesis is a multistage processes, due to
interaction between predisposing factors (e.g. H. Pylori
infection), as well as genetic and epigenetic abnormal-
ities (including activation of oncogenes and/or inactiva-
tion of suppressor genes), resulting in uncontrolled
cellular growth and dissemination.
Recent studies have shown that alterations in onco-
genes encoding tyrosine kinase receptors, play important
role in the pathogenesis of gastric carcinoma [10].
c-MET (or MET) is one of the tyrosine kinase recep-
tors' family, encoding a receptor for Hepatocyte Growth
Factor (HGF). Activation of c-MET by HGF and its sig-
naling pathways is pivotal for cellular morphogenesis, re-
generation, proliferation, migration, angiogenesis and
invasion [11]. c-MET is expressed in a variety of normal
epithelial and endothelial cells and mediated the bio-
logical activities of HGF [12].
Overexpression and amplification of c-MET have been
demonstrated in many tumors, including colorectal, thy-
roid, renal cell, ovary, breast, pancreas, prostate, liver,
and melanoma and in gastric carcinoma [13-16].
c-MET overexpression and amplification have been
reported in 18-82% of gastric carcinoma which studied
by immunofluorescence[12], immunohistochemistry
(IHC) [17-27], reverse transcription polymerase chain
reaction (RT-PCR) [17,28], Northern blot analysis [12]
and Southern blot analysis [19].
In most studies, overexpression of c-MET has been
correlated with poor prognosis and it has been regarded
as a negative prognostic factor [22,26-29]. Furthermore
c-MET overexpression has been strongly associated with
local invasiveness and distant metastasis[17], but in few
studies the results been discrepant [20,21].
This study was undertaken to examine immunohisto-
chemical expression of c-MET and its clinicopathological
association in gastric carcinoma, by using tissue micro-
array (TMA) technology.
Methods
In this cross sectional clinicopathological study, gastric
cancer patients treated by surgery in two university hos-
pitals (Firoozgar and Rasul) in Tehran-Iran, during a
2 years period of 2008 and 2009 were selected. The in-
clusion criteria were: proved diagnosis of primary gastric
adenocarcinoma and no history of neoadjuvant therapy.
The exclusion criteria were lack of suitable block for
TMA and insufficient medical records. Eligible speci-
mens were selected from the pathology laboratory files
in two hospitals and corresponding medical records
were reviewed after institutional research ethics’ com-
mittee agreement was obtained.The pathological features of tumors including location,
size, grade of differentiation, tumor classification accord-
ing to Lauren classification [30], TNM staging according
to American Joint Committee on Cancer/International
Union against Cancer (UICC) [31], neural and vascular
invasions and type of surgery were recorded.Tissue microarray construction
The tissue microarrays (TMA) were constructed as
described previously [32]. In each case, 5-μm H & E slides
were used to identify and mark out representative areas of
tumor tissue. From each corresponding paraffin- embed-
ded block, three representative tumor regions were
selected. Microarray samples with a diameter of 0.6 mm
were punched from selected regions of each “donor” block
and precisely arrayed into a new recipient paraffin block
using Tissue Arrayer Minicore (ALPHELYS, Plaisir,
France). The cores spaced 0.8 mm apart and in each re-
cipient TMA block, 50± 5 cores were inserted.Immunohistochemistry
Immunohistochemical staining was performed as
described previously[33]. On 4 μm tissue sections,
mouse monoclonal anti human c-MET (Novocastra-
United Kingdom) against external domain of beta chain
was used as primary antibody. Briefly, after deparaffini-
zation, endogenous peroxidase activity was inhibited by
hydrogen peroxide. Antigens were retrieved by autoclav-
ing and then incubated with primary antibody with an
optimal dilution of 1/30. Antigens were visualized using
Envision system (DAKO, Denmark) and diaminobenzi-
dine (DAB) (DAKO, Denmark). Finally TMA sections
were counterstained with hematoxylin. For processing of
the negative control slide, primary antibody was not
included. Human prostate tissue was used as positive
control for c- MET antibody.Evaluation of immunohistochemical staining
The cores with more than 10% tumoral tissue were con-
sidered eligible. Within each tissue spot (or core) the
most representative tumor region was evaluated and
scored by two pathologists that were blind to patients’
data. In case of cores with discrepant scores, cores were
re-examined by both pathologists to achieve a consensus
score. The membranous and cytoplasmic immunoreac-
tivity in tumoral cells was arbitrarily and semi quantita-
tively graded by considering the intensity of staining as
follow: 0 = negative; 1 =weak (cream); 2 =moderate (light
brown); and 3 = strong (brown and dark brown). Cases
with scores of 3 were regarded as “high expression”
whereas cases with scores of 0–2 were designated as
“low expression”.
Figure 2 Immunohistochemical staining using c-MET antibody
showing moderate (+2) cytoplasmic reaction in gastric cancer
cells (c-MET, x200).
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On completion of collection, data were coded and
entered twice into computer files to verify accuracy.
Analysis was carried out by SPSS software for windows,
version 16.0 (Chicago-IL-USA). Quantitative data are
presented as means ± standard deviation. Chi-square
test, Fisher exact test and t-test were used and P- value
less than 0.05 considered significant.
Results
One hundred and thirty paraffin blocks from 130 gastric
cancer patients were collected. Six cases missed in TMA
processing and were excluded. Finally 124 cases were
analyzed, containing 99 males and 25 females, with the
mean age of 61.5 ± 13.1 (range 30–100) years.
C-MET staining report
c-MET expression was localized in both cytoplasm and
membrane of tumoral cells (Figures 1, 2 and 3). Occasion-
ally nuclear staining was also seen in tumoral cells. Non
tumoral epithelial cells were also show weak to intermedi-
ate reactivity. In some cases, stroma was also stained. In
most of the tumors, uniform pattern of staining in epithe-
lial tumoral cells was observed. Our criterion for "high ex-
pression" of c-MET was strong (3+) staining of cytoplasm
and membrane in tumoral cells, which was diagnosed in 88
cases (71%). In high expression of c-MET, there was not
possible to differentiate membranous from cytoplasmic
staining.
"High expression" of c-MET was more in intestinal type
than diffuse type tumors, 77% versus 52%, respectively
(P= 0.04). It was also significantly more expressed in
deeply invaded tumors, 80% in pT3 and pT4 versus 58%
in pT1 and pT2 (P= 0.014). Gastric tumors with neural in-
vasion significantly show high expression of c-MET (83%)Figure 1 Immunohistochemical staining using c-MET antibody
showing weak (+1) cytoplasmic reaction in gastric cancer cells
(c-MET, x200).compared to those without neural invasion (53%)
(P= 0.002). c-MET high expression was also significantly
higher in stage 3 and 4 (80%) compared to stage 1 and 2
(44%) of gastric cancer (P= 0.044). In assessment of lymph
node metastasis and vascular invasion, there were a rela-
tive association (0.05<P< 0.1) between c-MET expres-
sion and both of them. There was no statistical difference
between c-MET expression and age, sex, tumor differenti-
ation, tumor location, tumor greatest dimension, distant
metastasis and vascular invasion. The relationship be-
tween clinical and pathological features and c-MET ex-
pression in gastric cancers are summarized in Table 1.Discussion and conclusions
In Iran, gastric cancer is the second most common can-
cer and the leading cause of cancer death and is anFigure 3 Immunohistochemical staining using c-MET antibody
showing strong (+3) and diffuse cytoplasmic reaction in gastric
cancer cells (c-MET, x200).
Table 1 Relationship between clinicopathological features
and c-MET expression in gastric cancers (n =124)
c-MET expression
Subjects variables High Low P-value
(n = 88) (n = 36)
Age (year) 62.3 ± 12.6 59.5 ±14.4 NS*
Sex
Male 72 27 NS
Female 16 9
Tumor location
Cardia (upper third) 22 8 NS
Body (middle third) 29 13
Antrum (lower third) 30 11
Diffuse 7 4
Tumor greatest dimension (cm) 5.9 ± 3.1 5.7 ± 3.8 NS
Tumor differentiation













pN0 14 11 0.065
pN1, 2, 3 74 25
Distant metastasis
Present 9 2 NS
Absent 79 34
Tumor stage (TNM)
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north and northwestern regions [3]. However about 80%
of the patients were presented in advanced stages and
did not gain any survival benefit from conventional ther-
apy [3-5]. Therefore new strategy based on the screening
of high risk population and achieving new prognostic
factors to predict the behavior of gastric tumor as well
as personalized target therapy are required.
The era of target therapy has started in 1990 by
Tamoxifen and until now more than 38 agents have
been introduced for various cancers, among them
anti-HER2/neu and anti c-kit therapy are the known
ones. While c-kit expression in gastric carcinoma is
very limited, Her2-neu expressed in less than 20% of
them [34,35], and efforts for finding other molecular
biomarker are currently in development.
c-MET is an oncogene that has gained attention as a
prognostic marker, and an indicator of metastasis and
poor prognosis as well as a good target for therapeutic
inhibition [16]. Until now many new anti-c-MET drugs
have been invented and most are in preclinical and clin-
ical testing [34,36].
Previous studies have been shown c-MET overexpres-
sion in selected patients indicates that certain patients
may be sensitive to targeted therapy [37]. Moreover it
has been confirmed that this protein overexpression is
significantly associated with high level of c-MET mRNA
and gene amplification [19,28].
In the current study, c-MET overexpression was
observed in 71% of gastric cancers and showed signifi-
cant statistical relationships with tumor type and depth
of tumor invasion as well as neural invasion and TNM
staging. It also showed a relative relationship with vascu-
lar invasion and lymph node metastasis.
As far as we know this is the first time that c-MET
oncogene is evaluated by Tissue microarray in Iran.
Tissue microarray technology has many advantages
including: facilitate the staining and the interpretation
and reduces the intra – and inter observer variation
of IHC interpretation and particularly saving the cost.
We used a semi automatic instrument but a new sim-
ple method is also introduced by using mechanical
pencil tips with much more low costs [38].
There were few studies using TMA to evaluate c-MET
by IHC in gastric cancer [18,21,39] and all were performed
in China.
Tang et al. studied c-MET expression in normal
gastric mucosa, intestinal metaplasia and gastric can-
cer and found c-MET overexpression in 68.8% of 232
gastric cancers. Its expression was significantly higher
than intestinal metaplasia. They did not find any rela-
tionship between c-MET expression in gastric cancer
with tumor stage, grade of differentiation or tumor
type [21].
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fied in cases of gastric carcinoma and matched normal
gastric mucosa, as well as cases with chronic atrophic
gastritis, intestinal metaplasia and dysplasia. c-MET
overexpression was found in about 66% of gastric carcin-
oma which was significantly higher than normal mucosa,
chronic gastritis, metaplasia and dysplasia. Its overex-
pression was associated with tumor type (more in intes-
tinal than in diffuse type), grade of differentiation and
lymph node metastasis [39].
Another study was also recently performed in China
by Li et al., and they reported c-MET expression in
82.4% of 114 gastric cancer. They found significant asso-
ciation between c-MET expression and advanced clinical
stage, lymph node metastasis and poor prognosis [18].
In contrast to Tang et al. [21], our findings are in agree-
ment with Li et al. [18] and Zhao et al. [39] studies and in
continuation of earlier studies that reported c-MET associ-
ation with poor prognosis and local invasiveness.
In present study we did not assess survival rate be-
cause of the short term of study and limitation of
patients' data, differences in patients' management and
lack of regular patients' follow up.
Another difference between the current study and
three above mentioned studies is in interpretation of
c-MET reactivity. Zhao et al. and Li et al. used double
score or product score (multiply intensity by area) with
different criteria and cut offs, and Tang et al. used only
the area of reactivity with the cut off of 10%; however
we used only "intensity" of reaction.
Traditionally, some authors have used double score or
H score (multiply intensity by area) in evaluation of IHC
staining, but we more agree with Tolgay et al. [40] that
due to the minute area (0.6 mm diameter) of the spots
in TMA and homogeneity in their reactions, ignoring
"area" is more appropriate in this setting.
In other studies using whole slide evaluation (without
using TMA), a spectrum of criteria have been used to
defining a positive reaction, but many used "area" with
various cut offs of 5% to 30% [17,19,22,28,29], and few
used a product score (intensity × area) [41].
It does not need to emphasis that with these various
arbitrary criteria, either in TMA or in whole slide assess-
ment, we will require a general consensus in regard to
evaluation of c-MET expression in gastric cancer. It
would not far that anti c-MET drugs become a part of
cancer management and defining eligible patient would
be our duty [37]. In fact standardization of various types
of antibodies used against c-MET would be another part
of this work. Until now, antibodies commonly used are
against extracellular alpha and beta subunits as well as
against intra cytoplasmic c-terminal. It is not clarified
that regardless of the name of producers, which type of
antibody is more sensitive or specific.Some studies reported more c-MET expression in dif-
fuse tumors than in intestinal type [41-43]. In contrast
to these results, Drebber et al. and Zhao et al. [29]
reported more c-MET expression in intestinal tumors,
and in agreement with them we also found a significant
expression of c-MET in intestinal tumors than in diffuse.
TNM staging system according to The American Joint
Committee on Cancer (AJCC)/International Union
against Cancer (UICC) produced the most reliable sys-
tem for predicting the survival of patients. Furthermore
lymphatic and vascular invasion were considered as poor
prognostic indicators [8,31,44,45].
In the present study, c-MET expression was signifi-
cantly related to depth of tumor invasion (pT), and
TNM staging and at least implied as a marker of local
invasiveness. As the depth of invasion and perforation of
serosa were introduced as independent prognostic fac-
tors [44], thus c-MET expression could be regarded as a
potential prognostic factor. This fact has been also
affirmed by other studies [17,19,23,28,46].
c-MET expression in present study showed no rela-
tionship to tumor differentiation which was in agree-
ment with Tang et al. results [21].
Several studies reported that c-MET expression had a
remarkable relationship with lymph node metastasis
[18,19,22,26,27,39] while in our study there was a rela-
tive relationship (P = 0.065) between these two variables.
One logical reason is that the average number of sepa-
rated lymph nodes in our cases was 11, which was under
the standard number of at least 15 per each gastrectomy
sample [8], and another reason was related to type of
surgery. The method of extended lymphadenectomy in
gastrectomy which widely used in Japan and other coun-
tries did not advocate in Iran. For example in one study
using extended lymphadenectomy an average of 39
lymph nodes was resected for each patient [29].
In the present study in agreement with previous studies,
association of c-MET overexpression and advanced stage
of gastric carcinoma was seen [12,13,17,19,28], while some
authors reported discrepant results [20,21,29] .
Nakajima et al. [19] found c-MET as a negative inde-
pendent prognostic factor and this finding was verified
by others [26-28] .
In the present study we did not find any association
between distant metastasis and c-MET expression,
which was in agreement with Huang et al. [28] study
and in contrast to Amemiya et al. [17] that showed all
gastric cancers with distant metastasis overexpressed
c-MET, but due to limited number of metastatic cases in
our study, their findings cannot be ruled out.
In conclusion c-MET oncogene protein was frequently
overexpressed in Iranian gastric carcinomas and it was
related to clinicopathological characteristics such as tumor
type, depth of invasion, neural invasion and TNM staging.
Sotoudeh et al. Diagnostic Pathology 2012, 7:57 Page 6 of 7
http://www.diagnosticpathology.org/content/7/1/57It can also support the idea that c-MET is a potential mar-
ker for target therapy in Iranian gastric cancer.
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